IN8bio shares target left unchanged from Laidlaw on glioblastoma study By Investing.com
(NASDAQ:INAB) IN8bio Inc. (NASDAQ:INAB) on Monday received a Buy rating and a $7.50 stock target from Laidlaw, following the latest presentation of clinical study results.
Over the weekend, the company updated its Phase 1 study of INB-200…